| Patents for C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629) |
|---|
| 01/28/2004 | EP1383865A2 Methods for the production of tyrosine, cinnamic acid and para-hydroxycinnamic acid |
| 01/28/2004 | EP1383863A2 Tissue growth method and apparatus |
| 01/28/2004 | EP1383862A2 Incubator and incubation method monitoring the organism to be incubated |
| 01/28/2004 | EP1383800A1 RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
| 01/28/2004 | EP1383798A2 Transporters and ion channels |
| 01/28/2004 | EP1383793A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/28/2004 | EP1383789A2 Proteins associated with cell growth, differentiation, and death |
| 01/28/2004 | EP1383784A1 A hepatitis b virus surface antigen mutant and methods of detection thereof |
| 01/28/2004 | EP1383783A2 Leinamycin biosynthesis gene cluster and its components and their uses |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383550A1 Scaffold matrix and tissue maintaining systems |
| 01/28/2004 | EP1383540A2 Methods and pharmaceutical compositions for healing wounds |
| 01/28/2004 | EP1383535A2 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 01/28/2004 | EP1383530A2 Laminin 5, 13 and 14 and uses thereof |
| 01/28/2004 | EP1383528A2 Epitope sequences |
| 01/28/2004 | EP1383393A2 Protein hydrolysates enriched in peptides having a carboxy terminal proline residue |
| 01/28/2004 | EP1383372A2 Bioluminescent plants and methods of making same |
| 01/28/2004 | EP0973869B1 Method for increasing the growth of plant cell cultures |
| 01/28/2004 | EP0968291B1 Antibody fragment-polymer conjugates |
| 01/28/2004 | EP0914345B1 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
| 01/28/2004 | EP0763124B1 Method for introducing nucleic acid in higher eukaryotic cells |
| 01/28/2004 | EP0724597B1 Ks-laminin and methods of use |
| 01/28/2004 | EP0690675B1 Nucleic acid coding for a tumor rejection antigen precursor |
| 01/28/2004 | CN1471586A Ex vivo generation of functional leukemia cells in a three-dimensional bioreactor |
| 01/28/2004 | CN1471583A Packaging of positive-strand RNA virus replicon particles |
| 01/28/2004 | CN1471582A Methods for producing a polypeptide using a consensus translational initiator sequence |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471578A Method of accumulating foreign gene product in plant seed at high level |
| 01/28/2004 | CN1471577A Transgenic plants containing molecular decoys that alter protein content therein |
| 01/28/2004 | CN1471576A Immortalized preosteoblasts and method for their production |
| 01/28/2004 | CN1471575A Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells |
| 01/28/2004 | CN1471356A Disease-resistant plants and method of constructing the same |
| 01/28/2004 | CN1470633A Totipotent somatic cell |
| 01/28/2004 | CN1470632A Optimized feeding suspension culture method for ammal cell |
| 01/28/2004 | CN1136314C Gene for transcription factor capable of altering characters of plants and use thereof |
| 01/27/2004 | US6683171 Contacting fkhsf specific nucleic acid probe under high stringency hybridizing conditions with at least one nucleic acid molecule from biological sample, detecting formation of hybrid, indicating presence of fkhsf nucleic acid molecule |
| 01/27/2004 | US6683160 Antibodies specific for Fkhsf gene products |
| 01/27/2004 | US6683157 Variant human α7 acetylcholine receptor subunit, and methods of production and use thereof |
| 01/27/2004 | US6683155 Purified and isolated polypeptide comprising specified amino acid sequence; regulating degradation of extracellular matrix |
| 01/27/2004 | US6683059 Constructs for suppression of oncogenic transformation, tumorigenesis and metastasis |
| 01/27/2004 | US6683057 Suppressing g beta gamma signaling; reducing intimal hyper-plasia following vein grafting and restenosis following arterial injury |
| 01/27/2004 | US6682931 Recovering cryopreserved conifer embryogenic cultures |
| 01/27/2004 | US6682929 Adenovector complementing cells |
| 01/27/2004 | US6682928 Cell is transformed to express on its surface a component which binds to an fc receptor of an effector cell used as a vehicle to increase an cell lysis and phagocytosis against an antigen associated with the cell |
| 01/27/2004 | US6682910 Gene expression, incubation; genetic engineering |
| 01/27/2004 | US6682909 Polypeptide for use in the diagnosis, treatment and prevention of hepatitis infections |
| 01/27/2004 | US6682907 Lentivirus have the unique capacity among retroviruses of infecting differentiated non mitotic cells and represent viral candidates of interest for the development of novel vectors |
| 01/27/2004 | US6682902 Human extracellular matrix polypeptides; polynucleotides; expression vectors; host cells; medical diagnosis; prostate cancer; detection of metastasis |
| 01/27/2004 | US6682894 Screening for preferential immunoglobulin; obtain human immunoglobulin receptor segment, incubate with antigen, detect complex formation |
| 01/27/2004 | US6682743 Genetically engineered virus for use in the propagation of preferential cells |
| 01/27/2004 | US6682742 Vector for integration of heterologous sequences into poxviral genomes |
| 01/27/2004 | US6682737 Monoclonal antibody having the same or overlapping epitope binding specificity as that of 3e2 secreted by hybridoma atcc hb 12075 |
| 01/27/2004 | US6682734 Anti-cd20 derived from transfectoma having atcc deposit numbers 69119 and hbe 1388 respectively; depletion of peripheral blood b cells |
| 01/27/2004 | US6682730 Transplants for myocardial scars |
| 01/27/2004 | CA2140663C Compounds which inhibit hiv replication |
| 01/27/2004 | CA2080428C A method for preparing a thromboplastin reagent from cultured cells that is suitable for use in the prothrombin time test |
| 01/27/2004 | CA2002607C Natural killer stimulatory factor |
| 01/26/2004 | CA2413275A1 Somatic pluripotent cells |
| 01/22/2004 | WO2004008100A2 Methods and media for controlling sialylation of proteins produced by mammalian cells |
| 01/22/2004 | WO2004007753A2 Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements |
| 01/22/2004 | WO2004007749A2 Methods and systems for extended in vitro culture of neuronal cells |
| 01/22/2004 | WO2004007735A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | WO2004007726A2 Brachyspira hyodysenteriae vaccine |
| 01/22/2004 | WO2004007724A1 Method of transporting protein to mitochondria |
| 01/22/2004 | WO2004007723A2 Genes |
| 01/22/2004 | WO2004007722A2 Transgenic animal expressing alzheimer’s tau protein |
| 01/22/2004 | WO2004007716A1 Method of isolating gpcr gene and novel gpcr gene |
| 01/22/2004 | WO2004007701A1 Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| 01/22/2004 | WO2004007700A1 Process for producing nerve cells |
| 01/22/2004 | WO2004007699A2 Method for preparing engineered tissue |
| 01/22/2004 | WO2004007698A1 Hemangioblast progenitor cells |
| 01/22/2004 | WO2004007697A2 Methods of implanting mesenchymal stem cells for tissue repair and formation |
| 01/22/2004 | WO2004007696A2 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 01/22/2004 | WO2004007686A2 Methods and transgenic mouse model for identifying and modulating factors involved in the production of reactive oxygen intermediates |
| 01/22/2004 | WO2004007683A2 Cellular reprogramming in peptide hydrogel and uses thereof |
| 01/22/2004 | WO2004007682A2 Methods and compositions for modulating t helper (th) cell development and function |
| 01/22/2004 | WO2004007674A2 Neuronal and retinal gene expression patterns |
| 01/22/2004 | WO2004007665A2 Methods for inducing differentiation of embryonic stem cells and uses thereof |
| 01/22/2004 | WO2004007547A2 Truncated tau proteins |
| 01/22/2004 | WO2004006951A1 Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| 01/22/2004 | WO2004006840A2 Three dimensional cell patterned bioploymer scaffolds and method of making the same |
| 01/22/2004 | WO2004006678A1 Spliceosome mediated rna trans-splicing for correction of skin disorders |
| 01/22/2004 | WO2004006659A1 High yielding soybean plants with increased seed protein plus oil |
| 01/22/2004 | WO2003102143A3 HUMAN COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1 (hCARM1) |
| 01/22/2004 | WO2003092615A3 Use of anti-cd1 antibodies for the modulation of immune responses |
| 01/22/2004 | WO2003092542A3 Injectable chondrocyte implant |
| 01/22/2004 | WO2003086290A3 Electroprocessing of materials useful in drug delivery and cell encapsulation |
| 01/22/2004 | WO2003076603A3 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions |
| 01/22/2004 | WO2003073843A3 Inbred embryonic stem-cell derived mice |
| 01/22/2004 | WO2003070933A3 Process of cell electrofusion |
| 01/22/2004 | WO2003066087A3 Kinases involved in the regulation of energy homeostasis |
| 01/22/2004 | WO2003058197A3 Detection of molecular interactions by beta-lactamase reporter fragment complementation |
| 01/22/2004 | WO2003054213A3 Non-human primate fc receptors and methods of use |
| 01/22/2004 | WO2003052098A3 Method for controlled induction of somatic mutations and use thereof in proteomics |
| 01/22/2004 | WO2003048205A3 Novel proteins with il-6 inhibiting activity |
| 01/22/2004 | WO2003045431A3 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
| 01/22/2004 | WO2003029453A3 Induction of gene expression by silencing of repressor genes |
| 01/22/2004 | WO2003020889A3 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 01/22/2004 | WO2003001883A3 Gaba b1a receptor disruptions, compositions and methods relating thereto |
| 01/22/2004 | WO2002099120A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |